Topics

Glioblastoma | Treatment | Targeted therapy | Ifabotuzumab

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Ifabotuzumab

Gan HK, Cher L, Inglis PL, Lwin Z, Gunjur A, Balasubramanian A, Schmidt A, Wichmann CW, Guo N, Lee ST, Thomas P, Scott FE, Shard C, Fluck K, Coombs N, Palmer J, Vail ME, Allen S, Patil A, Pal B, O'Keefe GJ, Gong SJ, Ninatti G, Day BW, Gomez GA, Janes PW, Scott AM.
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.
Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-25-3608. PMID: 42268288. Trial registration ID: NCT00749638(?)˰ ˍ